To observe the pharmacokinetic profiles of benapenem and its major metabolites in healthy volunteers after continuous multiple-dose benapenem, providing evidence for phase Ⅱ clinical study.
A single-center, randomized, open-label, and dose escalation trial design is used in the multiple-dose tolerability and pharmacokinetic studies. The tolerability and pharmacokinetic studies are performed simultaneously. Three doses, 250 mg, 500 mg, and 1000 mg are proposed for multiple-dose tolerability and pharmacokinetic studies. The subjects are divided into two groups, 12 subjects in each group, half males and half females. 250 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed. After completion of observation and confirming that the drug can be safely tolerated, study on 1000 mg group is then performed. Each subject only receives one dose, intravenous drip, once daily, for 7 consecutive days. During the trial, close attention is paid to the tolerability of subjects, and blood samples 4 mL is collected from cubital vein respectively before dosing, 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 3 h, 5h, 8 h, 12 h, and 24 h after dosing on Day 1 (0 h); before dosing (0 h), 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 3 h, 5 h, 8 h, 12 h, 24 h, 36 h, and 48 h after dosing on Day 7 for pharmacokinetic study. Blood samples are collected before dosing on Day 4, 5 and 6 to determine the trough concentration for observing the pharmacokinetic profiles of benapenem and its major metabolites in the body after continuous dosing. The next dose group can be studied only when the observation of the previous dose group is completed and it is confirmed that the drug is safely tolerated
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
36
Banapenem to be used anti-infection
AUC(0-24) of Benapenem
AUC(0-24) is the area under the curve from time 0 to 24 hour
Time frame: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hours after Dosing
Maximum observed plasma concentration (Cmax) of Benapenem
Maximum observed plasma concentration (Cmax) of Benapenem in healthy subjects
Time frame: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hours after Dosing
Time to maximum observed plasma concentration (tmax) of Benapenem
Time to maximum observed plasma concentration (tmax) of Benapenem in healthy subjects
Time frame: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hours after Dosing
Time to elimination half-life (t1/2) of Benapenem
Time to elimination half-life (t1/2) of Benapenem in healthy subjects
Time frame: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hours after Dosing
Number of subjects with clinically significant findings in vital signs
Vitals signs such as systolic and diastolic blood pressure, heart rate, and pulse rate will be measured in a semi-supine position after 5 minutes of rest
Time frame: Screening, Day1, Day2, Day4 after Dosing
Number of subjects with clinically significant findings in laboratory parameters
Hematology and Clinical Chemistry and Urine routine abnormalities will be monitored
Time frame: Screening, Day1, Day2, Day4 after Dosing
Number of subjects with clinically significant 12-lead ECGs
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals.
Time frame: Screening, Day1, Day2, Day4 after Dosing
Number of subjects with adverse events and serious adverse events
All adverse events will be monitored in each group subjects
Time frame: From Screening to Day 4 after dosing